MeSH tree: D27.505.954.248
Researchers at The University of Texas MD Anderson Cancer Center have identified a key enzyme—RNase H2—that helps triple-negative breast cancer (TNBC) cells survive high levels of DNA replication stress. Because many breast ...
May 4, 2026
0
12
Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern ...
May 4, 2026
0
6
Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most important defense systems is homologous recombination, a high-precision repair pathway that fixes broken DNA ...
Apr 30, 2026
0
7
Immune checkpoint inhibitors (ICIs) have transformed treatment for many types of cancer. In some patients, however, ICIs are associated with immune-related complications that can affect the kidneys. These complications sometimes ...
Apr 22, 2026
0
4
Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in patients who experienced ...
Apr 21, 2026
0
4
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found ...
Apr 20, 2026
0
4
Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 ...
Apr 20, 2026
0
3
An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small ...
Apr 20, 2026
0
4
A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a ...
Apr 20, 2026
0
3
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
Apr 20, 2026
0
6
